These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28797172)

  • 21. An industry perspective on tiered approach to the investigation of metabolites in drug development.
    Huskey SE; Li W; Mangold JB; Flarakos J
    Bioanalysis; 2014 Mar; 6(5):617-28. PubMed ID: 24620804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolite identification and profiling in drug design: current practice and future directions.
    Zhang Z; Zhu M; Tang W
    Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis.
    Nedderman AN; Wright P
    Bioanalysis; 2010 Jul; 2(7):1235-48. PubMed ID: 21083237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.
    Caceres-Cortes J; Reily MD
    Bioanalysis; 2010 Jul; 2(7):1263-76. PubMed ID: 21083239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industry.
    Nadanaciva S; Will Y
    Curr Drug Targets; 2011 Jun; 12(6):774-82. PubMed ID: 21275886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 27. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug-like property concepts in pharmaceutical design.
    Di L; Kerns EH; Carter GT
    Curr Pharm Des; 2009; 15(19):2184-94. PubMed ID: 19601822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overtaking the DILI Model-T.
    Opar A
    Nat Rev Drug Discov; 2012 Aug; 11(8):585-6. PubMed ID: 22850771
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug metabolites in safety testing.
    Baillie TA; Cayen MN; Fouda H; Gerson RJ; Green JD; Grossman SJ; Klunk LJ; LeBlanc B; Perkins DG; Shipley LA
    Toxicol Appl Pharmacol; 2002 Aug; 182(3):188-96. PubMed ID: 12229863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.
    Faller B; Wang J; Zimmerlin A; Bell L; Hamon J; Whitebread S; Azzaoui K; Bojanic D; Urban L
    Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):823-33. PubMed ID: 17125403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries.
    Modi S; Hughes M; Garrow A; White A
    Drug Discov Today; 2012 Feb; 17(3-4):135-42. PubMed ID: 22063083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals.
    Naito S; Furuta S; Yoshida T; Kitada M; Fueki O; Unno T; Ohno Y; Onodera H; Kawamura N; Kurokawa M; Sagami F; Shinoda K; Nakazawa T; Yamazaki T
    J Toxicol Sci; 2007 Oct; 32(4):329-41. PubMed ID: 17965548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Requirements for a lead compound to become a clinical candidate.
    Hefti FF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: Role of Drug Metabolism and its Mediated DDI in Drug Efficacy and Safety Part 2.
    Liu C; He X
    Curr Drug Metab; 2015; 16(10):848-9. PubMed ID: 26652253
    [No Abstract]   [Full Text] [Related]  

  • 37. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting drug side-effects by chemical systems biology.
    Tatonetti NP; Liu T; Altman RB
    Genome Biol; 2009; 10(9):238. PubMed ID: 19723347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity testing in chemical safety evaluation.
    Bus JS
    Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.2. PubMed ID: 23045142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.